Literature DB >> 18178292

Colonic antigen administration induces significantly higher humoral levels of colonic and vaginal IgA, and serum IgG compared to oral administration.

Emma L McConnell1, Abdul W Basit, Sudaxshina Murdan.   

Abstract

It was hypothesised that different immune responses would be obtained following oral and colonic antigen administration, due to the significant differences in the immune environments of the colon and that of the small intestine. Antigen administration to the mouse colon (via the rectum) was found to generate different profiles of immune responses compared to oral administration (by gavage). Serum IgG and IgA levels in faecal and colonic extracts and in the vaginal wash were significantly higher following colonic administration of soluble (plus cholera toxin B subunit adjuvant) or encapsulated (in microspheres) antigen while smaller differences were seen in the small intestinal IgA levels. This reflects the compartmentalisation within the common mucosal immune system and suggests that the colon may be an appropriate vaccination target for diseases of the colon, and for sexually and vertically transmitted diseases. Antigen was also administered rectally and intramuscularly as controls. Colonic administration was superior to rectal administration, possibly due to the greater amounts of lymphoid tissue in the colon, although the immune response profiles were similar.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18178292     DOI: 10.1016/j.vaccine.2007.11.071

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization.

Authors:  Pooja Ralli-Jain; Delia Tifrea; Chunmei Cheng; Sukumar Pal; Luis M de la Maza
Journal:  Vaccine       Date:  2010-09-25       Impact factor: 3.641

2.  Induction of protection against vaginal shedding and infertility by a recombinant Chlamydia vaccine.

Authors:  Jennifer R Carmichael; Sukumar Pal; Delia Tifrea; Luis M de la Maza
Journal:  Vaccine       Date:  2011-05-24       Impact factor: 3.641

3.  Oral vaccines: directed safe passage to the front line of defense.

Authors:  Qing Zhu; Jay A Berzofsky
Journal:  Gut Microbes       Date:  2013-03-14

Review 4.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

5.  Vaccination with the recombinant major outer membrane protein elicits long-term protection in mice against vaginal shedding and infertility following a Chlamydia muridarum genital challenge.

Authors:  Sukumar Pal; Maria I Cruz-Fisher; Chunmei Cheng; Jennifer R Carmichael; Delia F Tifrea; Olga Tatarenkova; Luis M de la Maza
Journal:  NPJ Vaccines       Date:  2020-10-01       Impact factor: 7.344

6.  A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge.

Authors:  Chunmei Cheng; Sukumar Pal; Delia Tifrea; Zhenyu Jia; Luis M de la Maza
Journal:  Microbes Infect       Date:  2013-11-27       Impact factor: 2.700

7.  A Recombinant Chlamydia trachomatis MOMP Vaccine Elicits Cross-serogroup Protection in Mice Against Vaginal Shedding and Infertility.

Authors:  Delia F Tifrea; Sukumar Pal; Luis M de la Maza
Journal:  J Infect Dis       Date:  2020-01-02       Impact factor: 5.226

Review 8.  Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design.

Authors:  Thorsten Demberg; Marjorie Robert-Guroff
Journal:  Int Rev Immunol       Date:  2009       Impact factor: 5.311

9.  5-Aminolevulinic Acid as a Novel Therapeutic for Inflammatory Bowel Disease.

Authors:  Vipul Yadav; Yang Mai; Laura E McCoubrey; Yasufumi Wada; Motoyasu Tomioka; Satofumi Kawata; Shrikant Charde; Abdul W Basit
Journal:  Biomedicines       Date:  2021-05-20

10.  Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection.

Authors:  Qing Zhu; James Talton; Guofeng Zhang; Tshaka Cunningham; Zijian Wang; Robert C Waters; James Kirk; Bärbel Eppler; Dennis M Klinman; Yongjun Sui; Susan Gagnon; Igor M Belyakov; Russell J Mumper; Jay A Berzofsky
Journal:  Nat Med       Date:  2012-07-15       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.